Cover Image

Impact of sacubitril/valsartan on the long-term incidence of ventricular arrhythmias in chronic heart failure patients

Background: Sacubitril/valsartan decreased the risk of sudden cardiac death (SCD) in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, long-term data are sparse. Objective: The aim of the present study was to compare the incidence of life-threatening arrhythmias...

Full description

Saved in:
Bibliographic Details
Main Authors: El-Battrawy, Ibrahim (Author) , Pilsinger, Christina (Author) , Liebe, Volker (Author) , Lang, Siegfried (Author) , Kuschyk, Jürgen (Author) , Zhou, Xiao-Bo (Author) , Borggrefe, Martin (Author) , Röger, Susanne (Author) , Akın, Ibrahim (Author)
Format: Article (Journal)
Language:English
Published: 2 October 2019
In: Journal of Clinical Medicine
Year: 2019, Volume: 8, Issue: 10
ISSN:2077-0383
DOI:10.3390/jcm8101582
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.3390/jcm8101582
Verlag, kostenfrei, Volltext: https://www.mdpi.com/2077-0383/8/10/1582
Get full text
Author Notes:Ibrahim El-Battrawy, Christina Pilsinger, Volker Liebe, Siegfried Lang, Jürgen Kuschyk, Xiaobo Zhou, Martin Borggrefe, Susanne Röger and Ibrahim Akin
Description
Summary:Background: Sacubitril/valsartan decreased the risk of sudden cardiac death (SCD) in patients suffering from heart failure with reduced ejection fraction (HFrEF). However, long-term data are sparse. Objective: The aim of the present study was to compare the incidence of life-threatening arrhythmias consisting of ventricular tachycardia and/or ventricular fibrillation before and after initiation of sacubitril/valsartan treatment. Methods: Out of 12,000 patients with HFrEF from 2016&ndash;2018, 148 patients were newly prescribed sacubitril/valsartan, but the long-term data of only 127 patients were available and included in this study. Results: Patients with an average age of 66.8 &plusmn; 12.1 had a median left ventricular ejection fraction (LVEF) of 25% (interquartile range (IQR) 5.00&ndash;45.00) and 30% (IQR 10.00&ndash;55.00, p < 0.0005) before and after sacubitril/valsartan treatment, respectively. Systolic blood pressure decreased from 127.93 &plusmn; 22.01 to 118.36 &plusmn; 20.55 mmHg (p = 0.0035) at 6 months of follow-up. However, in 59 patients with a long-term outcome of 12 months, ventricular arrhythmias persistently increased (ventricular fibrillation from 27.6 to 29.3%, ventricular tachycardia (VT) from 12% to 13.8%, and nonsustained VT from 26.6 to 33.3%). Conclusions: Sacubitril/valsartan does not reduce the risk of ventricular tachyarrhythmias in chronic HFrEF patients over 12 months of follow-up.
Item Description:Gesehen am 10.12.2019
Physical Description:Online Resource
ISSN:2077-0383
DOI:10.3390/jcm8101582

Similar Items